Toxic Shock Syndrome

Toxic shock syndrome (TSS) is a rapidly progressive, toxin-mediated multisystem illness driven by exotoxin-producing Staphylococcus aureus or Streptococcus pyogenes (group A streptococcus, GAS) — two genuinely distinct syndromes, staphylococcal TSS and streptococcal TSS (STSS), that share a common underlying mechanism (a bacterial superantigen bypassing normal antigen processing to trigger massive, nonspecific T-cell activation and a cytokine storm) but differ meaningfully in typical clinical context, case-fatality rate, and treatment nuance.^[1][2] Both are true medical emergencies: shock and multi-organ failure can develop within hours of the first symptoms, and streptococcal TSS carries a case-fatality rate as high as 30-70%, dramatically higher than the under-3% mortality typical of staphylococcal TSS.^[3][4]

The historically well-known association with menstruation and superabsorbent tampon use is real but has become a less dominant presentation since tampon absorbency and composition changed in the 1980s-90s; non-menstrual TSS — from surgical wounds, burns, skin and soft-tissue infections, nasal packing after nasal surgery, and postpartum infection — is now at least as important and should never be under-considered simply because a patient is not menstruating.^[5] This chapter covers both syndromes' presentation and diagnostic criteria, the essential and time-critical role of source control, empiric antibiotic therapy combining an antibacterial agent with clindamycin specifically for its toxin-production-suppressing mechanism, intravenous immunoglobulin (IVIG) as an adjunct in severe or refractory disease, and the aggressive supportive, ICU-level care this true emergency demands.

Pathophysiology — why this is a toxin-mediated emergency, not a typical infection

The defining feature of TSS is the superantigen: a bacterial exotoxin (toxic shock syndrome toxin-1 [TSST-1] in most staphylococcal TSS; streptococcal pyrogenic exotoxins A, B, and C, among others, in streptococcal TSS) that bypasses the normal, highly selective process of antigen presentation. Rather than being processed and presented within the groove of an MHC class II molecule to a small number of antigen-specific T cells, a superantigen binds directly to the outside of MHC class II and to the T-cell receptor's variable beta chain — activating up to 20-30% of the entire T-cell population, compared with well under 0.01% for a conventional antigen.^[4] The result is a massive, nonspecific cytokine storm (interleukin-1, interleukin-2, tumor necrosis factor-alpha, interferon-gamma) that drives capillary leak, vasodilation, hypotension, and rapid multi-organ dysfunction — a process that can unfold over hours, and one where clinically significant, culturable bacteremia is often absent in staphylococcal TSS even though the toxin's effects are severe.^[4]

Clinical presentation

Both syndromes classically present with abrupt-onset high fever (≥38.9°C/102°F), a diffuse, blanching macular erythroderma often described as looking like a sunburn — most prominent on the trunk and proximal extremities, and frequently accompanied by conjunctival and oropharyngeal mucosal hyperemia (and, in some staphylococcal cases, a "strawberry tongue") — together with rapidly progressive hypotension and evidence of multi-organ involvement: profuse vomiting and/or diarrhea early in the illness, severe myalgia, disorientation or altered mental status without a focal neurologic cause, and laboratory evidence of renal, hepatic, or hematologic dysfunction.^[1][2] Desquamation — classically sheet-like peeling of the palms and soles — is a real and specific finding, but it is a late one, typically appearing 1-2 weeks after illness onset; it is useful for retrospectively confirming the diagnosis but must never be waited for before starting treatment.^[1]

• Menstruation with tampon use, particularly prolonged wear or a higher-absorbency product — a real but now less dominant risk factor than in the 1980s, given changes to tampon composition and absorbency standards since then.^[5]
• Any other vaginal barrier device left in place: a menstrual cup, diaphragm, cervical cap, or contraceptive sponge.
• Nasal packing after nasal or sinus surgery, or for epistaxis control.^[4]
• Any surgical wound, especially one with a retained foreign body, hematoma, or seroma; postpartum or post-abortion infection.
• Burns, and any skin or soft-tissue infection or abscess with S. aureus or S. pyogenes — the single most common source/risk factor for TSS overall.^[4]
• Recent influenza — staphylococcal TSS is a recognized, serious complication of secondary staphylococcal infection following influenza.
• Varicella (chickenpox) in children — a recognized portal of entry for invasive, toxin-producing GAS.
• Nonsteroidal anti-inflammatory drug (NSAID) use around a soft-tissue injury, surgical site, or varicella lesion — an association with more severe group A streptococcal disease that is biologically plausible and supported by experimental and some clinical data, though not universally confirmed prospectively (see Common Errors to Avoid).^[6]
• A prior episode of menstrual TSS without laboratory-confirmed seroconversion (development of protective antibody to the causative toxin) — associated with a real, clinically meaningful risk of recurrence with continued tampon use.^[7]
• Diabetes, immunosuppression, and other chronic illness — general susceptibility factors for more severe invasive staphylococcal or streptococcal disease.
• Young age (for staphylococcal TSS specifically) — older adults are more likely to have already seroconverted to protective anti-TSST-1 antibody from prior subclinical colonization/exposure.

• Fever, diffuse macular erythroderma, and hypotension or shock in any patient, menstruating or not.
• Any menstruating patient using a tampon (or menstrual cup, diaphragm, or similar device) with an unexplained febrile illness — ask directly and remove the device immediately, even before the rest of the workup is complete.
• Any patient with nasal packing, wound packing, or other retained material with unexplained fever, rash, or hemodynamic instability.
• Pain that is disproportionate to visible skin findings, rapidly spreading erythema, bullae, skin necrosis, or crepitus over a wound or soft-tissue area — classic red flags for necrotizing fasciitis, which requires emergent surgical exploration and is a recognized precursor to streptococcal TSS.^[8]
• A postpartum or post-surgical patient with unexplained fever and hypotension — examine the wound/uterus directly rather than attributing the picture to a more common postoperative or postpartum complication.
• A child with varicella and new high fever, severe localized pain, or rapid clinical deterioration.
• Any sign of multi-organ dysfunction (altered mental status, oliguria, coagulopathy, respiratory distress) accompanying a compatible febrile rash illness.

History and examination

Ask specifically about menstrual status and tampon/menstrual cup/diaphragm use (and confirm removal), recent surgery, wounds, burns, nasal packing, postpartum status, and varicella exposure — none of these should be assumed absent simply because the patient does not volunteer them. Perform a complete skin and mucosal examination, including the palms, soles, and conjunctivae/oropharynx, and inspect every wound, surgical site, and area of nasal packing directly rather than relying on the chart. In a patient with any possible soft-tissue focus, actively assess for the red flags of necrotizing infection: pain out of proportion to examination findings, rapidly advancing erythema, bullae, skin discoloration/necrosis, and crepitus.

Laboratory testing

Obtain a complete blood count (leukocytosis with a marked left shift/bandemia is typical), comprehensive metabolic panel (renal and hepatic function), creatine kinase (muscle involvement/myositis), coagulation studies including fibrinogen (disseminated intravascular coagulation is a recognized complication, especially in STSS), lactate, and two sets of blood cultures before the first antibiotic dose whenever feasible without materially delaying treatment — positive far more often in streptococcal TSS than in staphylococcal TSS, where a negative blood culture does not argue against the diagnosis.^[4] Culture any wound, site of packing, or vaginal/cervical swab as applicable. Hypocalcemia can be prominent and clinically significant, and should be actively corrected.

Imaging

Imaging should never delay urgent surgical consultation or source control when clinical suspicion for a necrotizing or deep soft-tissue process is high. CT or MRI can help delineate the extent of soft-tissue involvement or identify an occult deep collection once the patient is stable enough, but a clinical picture strongly suggestive of necrotizing fasciitis warrants emergent surgical exploration regardless of imaging availability or findings.^[8]

Diagnostic criteria

Both syndromes have formal CDC surveillance case definitions that combine clinical and laboratory criteria; they are genuinely useful for organizing the bedside assessment even though, in practice, treatment should never wait for a case to be formally classified.

^[1]

^[2] A simplified, clinically oriented version of the STSS definition — hypotension plus at least two of renal impairment, coagulopathy, liver dysfunction, ARDS, or a generalized erythematous rash — is used in current Canadian Paediatric Society guidance and is consistent with the CDC definition above.^[3]

• Reverse shock and prevent progressive multi-organ failure with immediate, aggressive resuscitation.
• Achieve source control without delay: physically remove any retained tampon, menstrual cup, diaphragm, nasal packing, or wound packing, and obtain urgent surgical debridement of any infected or necrotic soft-tissue focus — this is genuinely time-critical and is not interchangeable with antibiotics.
• Start empiric combination antibiotic therapy immediately, pairing an antibacterial agent with clindamycin specifically to suppress ongoing toxin production.
• Consider IVIG early in severe or refractory disease, particularly streptococcal TSS with persistent shock, to help neutralize circulating superantigen.
• Provide ICU-level monitoring and organ support, anticipating rapid deterioration even after initial stabilization appears to begin.
• De-escalate to targeted therapy once an organism and susceptibilities are known, and confirm an appropriate total treatment duration.
• Arrange chemoprophylaxis for close contacts of a confirmed severe/invasive streptococcal case, and complete public health reporting.
• Counsel survivors of menstrual TSS on the real risk of recurrence with continued tampon use.

Why clindamycin is added to every regimen — a genuinely important, non-obvious pharmacologic point

Clindamycin's role in TSS is not simply another antibacterial option — it is added specifically for a distinct, additive mechanism. As a ribosomal (50S subunit) protein-synthesis inhibitor, clindamycin directly suppresses bacterial exotoxin production (TSST-1 in staphylococcal disease; streptococcal pyrogenic exotoxins and streptolysin O in streptococcal disease) — a laboratory finding first demonstrated for TSST-1 in 1984 and since shown for multiple staphylococcal and streptococcal toxins.^[9] This effect is genuinely independent of, and additive to, clindamycin's modest antibacterial activity: a classic experimental model of streptococcal myositis found that delayed clindamycin dramatically outperformed delayed penicillin (survival of 70-100% versus no better than untreated controls once treatment was delayed even a few hours), an effect attributed in part to the so-called Eagle effect — beta-lactams require actively dividing bacteria with intact penicillin-binding proteins to work, and lose potency against the large, stationary-phase bacterial populations typical of an established toxin-producing infection, while clindamycin's protein-synthesis-inhibiting and toxin-suppressing mechanism does not depend on this.^[10] In practice, this means clindamycin should be started alongside the primary antibacterial agent from the very first dose in every confirmed or strongly suspected case of either syndrome, not reserved as a second-line addition if the patient fails to improve.

Intravenous immunoglobulin (IVIG)

IVIG is an adjunct, not a substitute for antibiotics or source control, and works by neutralizing circulating superantigen before it can continue driving T-cell activation and cytokine release. The evidence base is genuinely stronger for streptococcal TSS: a systematic review and meta-analysis of clindamycin-treated STSS patients found IVIG was associated with a mortality reduction from 33.7% to 15.7% (risk ratio 0.46, 95% CI 0.26-0.83) — a number needed to treat of roughly 6 to prevent one additional death.^[11] Current Canadian Paediatric Society guidance recommends considering IVIG on the day of clinical presentation for streptococcal TSS, using either immunoglobulin (human) 1-2 g/kg as a single dose, or 150-500 mg/kg/day for 5-6 days.^[3] For staphylococcal TSS, the supporting evidence is considerably weaker and more mixed — staphylococcal disease may respond less reliably to IVIG than streptococcal disease — but it is still reasonably considered, often at a similar or higher single-dose regimen, for a patient with persistent shock or organ dysfunction despite adequate source control and antibiotics.^[4]

• Immediate removal of any retained tampon, menstrual cup, diaphragm, cervical cap, or contraceptive sponge — a simple, time-critical step that is easy to miss if the patient's menstrual/device history isn't asked about directly.
• Immediate removal of nasal or wound packing in any patient in whom it is present, regardless of how recently it was placed or how "routine" the original procedure was.
• Urgent surgical consultation and debridement of any confirmed or strongly suspected necrotizing soft-tissue infection, myositis, or infected surgical/postpartum wound — repeated as needed, since a single debridement is not always sufficient, and this is co-equal source control alongside antibiotics, not an adjunct to them.^[8]
• Aggressive isotonic crystalloid fluid resuscitation, titrated to hemodynamic response, urine output, and lactate clearance, recognizing that capillary leak from the underlying cytokine storm can create very large ongoing fluid requirements.
• ICU admission with invasive hemodynamic monitoring for any patient with hypotension or organ dysfunction, given the genuine risk of rapid deterioration even after apparent initial stabilization.
• Respiratory support, up to and including mechanical ventilation, for ARDS or airway compromise from altered mental status.
• Renal replacement therapy if acute kidney injury progresses despite adequate resuscitation.
• Correction of hypocalcemia and other electrolyte derangements, which can be clinically significant in severe disease.
• Avoid nonselective NSAIDs for analgesia or antipyresis once significant soft-tissue infection or streptococcal disease is suspected; use acetaminophen preferentially (see Common Errors to Avoid).
• Droplet/contact precautions for confirmed invasive GAS until 24 hours of effective antibiotic therapy has been completed, and public health reporting of confirmed invasive group A streptococcal disease and TSS, which are reportable conditions.
• Chemoprophylaxis coordination for close contacts of a confirmed severe/invasive streptococcal case (see Special Populations).

Pediatrics

Apply the same principles as in adults, with weight-based dosing throughout. Varicella is a recognized portal of entry for invasive, toxin-producing GAS in children, and a febrile, unwell child with chickenpox and new, severe, localized pain deserves the same urgent evaluation as any other compatible presentation.^[6] Avoid nonselective NSAIDs (including ibuprofen) for fever or pain control in a child with varicella or a possible soft-tissue infection — use acetaminophen instead.^[6] IVIG dosing in children follows the same regimens used in adults: immunoglobulin (human) 1-2 g/kg as a single dose, or 150-500 mg/kg/day for 5-6 days, considered on the day of presentation for streptococcal TSS.^[3]

Close contacts of a confirmed severe/invasive streptococcal case — chemoprophylaxis

Household and other close contacts of a patient with confirmed streptococcal TSS or another severe/invasive GAS infection (e.g., necrotizing fasciitis) carry a real, if small, increased risk of subsequent invasive GAS disease themselves, and current Canadian Paediatric Society guidance recommends chemoprophylaxis be offered.^[3] First-line cephalexin 25-50 mg/kg/day (maximum 1 g/day) for 10 days. Beta-lactam allergy clarithromycin or clindamycin. Start prophylaxis as soon as possible — ideally within 24 hours of identifying a close contact — though it can still reasonably be offered up to about 7 days after the last contact with the index case.^[3]

Pregnancy and postpartum

Postpartum staphylococcal or streptococcal TSS is a genuine, time-critical obstetric emergency, most often arising from a uterine, wound, or perineal source — do not let obstetric considerations delay urgent source control (wound exploration, evaluation for retained products of conception) or the first dose of antibiotics. vancomycin (IV), cloxacillin, penicillin G, and clindamycin are all generally considered compatible with pregnancy and breastfeeding at standard doses; involve obstetrics and infectious diseases jointly for a critically unwell pregnant or postpartum patient, and do not withhold IVIG on the basis of pregnancy alone when it is otherwise indicated for refractory shock.

Menstrual TSS survivors — recurrence risk

A patient recovering from menstrual TSS faces a real, clinically meaningful risk of recurrence with continued tampon use — in one of the earliest and most detailed cohorts, roughly a quarter of patients had at least one recurrent episode during a subsequent menstrual period, and recurrence was less common among patients who had actually received an appropriate beta-lactamase-resistant antistaphylococcal antibiotic (reinforcing that antibiotics matter in this condition beyond simple source removal).^[7] Counsel every survivor explicitly to avoid tampons, menstrual cups, diaphragms, and similar products going forward, and consider referral for antibody/seroconversion assessment where available, since a documented lack of seroconversion to the causative toxin is associated with a substantially higher recurrence risk.

• Reassess hemodynamics, urine output, mental status, and the extent of any rash/skin findings at least every few hours during the first 24-48 hours of critical illness, alongside serial renal, hepatic, and coagulation studies.
• Expect meaningful clinical improvement within about 24-48 hours of adequate source control and antibiotics (plus IVIG where given) — a plateau or worsening picture should prompt reassessment rather than simply continuing the same plan (see Treatment Failure/Next Step).
• Reassess any debrided wound or surgical site regularly; repeat debridement is common and expected in necrotizing infection, not a sign that the original plan failed.
• Confirm total antibiotic duration is individualized to the source, organism, and clinical trajectory — commonly around 10-14 days for uncomplicated disease once source control is adequate, longer with bacteremia, endocarditis, retained deep infection, or necrotizing fasciitis requiring staged debridement.^[4]
• Counsel patients and families that desquamation, typically beginning 1-2 weeks after illness onset and classically involving the palms and soles, is an expected part of recovery — not a sign of ongoing or worsening infection.^[1]
• Confirm chemoprophylaxis has been offered and, where accepted, completed for close contacts of a confirmed severe/invasive streptococcal case, and that public health reporting has been completed.^[3]
• Before discharge, explicitly counsel any survivor of menstrual TSS on tampon/device avoidance and the real recurrence risk with continued use.^[7]
• Arrange follow-up for any organ dysfunction present at discharge (renal function, cardiac function, cognitive/neurologic status) and for reconstructive or wound-care needs after extensive debridement.

1. Persistent shock or escalating vasopressor requirement despite adequate fluids, source control, and antibiotics: escalate vasopressor therapy (add vasopressin or epinephrine), give IVIG if not already given (or consider repeat dosing), and actively reassess for an undrained or incompletely controlled source with repeat imaging or surgical re-exploration.
2. Expanding or persistent soft-tissue necrosis, or a wound that continues to look unhealthy: return to the operating room for repeat debridement — broadening antibiotics is not a substitute for adequate surgical source control.^[8]
3. A retained foreign body not fully identified or removed on the first search (a second tampon, a fragment of packing material): re-examine directly rather than assuming the first search was complete.
4. Culture-negative presentation with high clinical suspicion, especially in staphylococcal TSS: continue empiric therapy — a negative blood or wound culture does not exclude the diagnosis, particularly if antibiotics were started, or the primary site irrigated/debrided, before cultures were obtained.^[4]
5. Recurrent menstrual TSS: strongly counsel against further tampon, menstrual cup, or diaphragm use, and consider referral for antibody/seroconversion assessment where available.^[7]
6. A presentation that does not fully fit the case definition, or an atypical course: reassess against the complete diagnostic criteria and actively consider mimics — Kawasaki disease or multisystem inflammatory syndrome in a child, a severe drug reaction, or another cause of septic or distributive shock — without abandoning empiric treatment if genuine suspicion for TSS remains.

• Waiting for desquamation to "confirm" the diagnosis before starting treatment — it is a real but late finding that appears 1-2 weeks after onset and must never delay care.^[1]
• Not actively asking about, or forgetting to search for and remove, a retained tampon, menstrual cup, diaphragm, or nasal/wound packing — an easy-to-miss, genuinely time-critical step.
• Treating suspected staphylococcal or streptococcal TSS with a beta-lactam or vancomycin alone, without adding clindamycin from the first dose — this forfeits a real, mechanistically distinct toxin-suppression benefit.^[9][10]
• Assuming TSS is exclusively a "menstrual disease" and not considering it in a non-menstruating patient, a man, a child, or a postmenopausal woman with a compatible wound, surgical, or burn source.
• Using nonselective NSAIDs (e.g., ibuprofen) for pain or fever control once a significant soft-tissue infection or streptococcal disease is suspected — prefer acetaminophen; the evidence for causing worse outcomes is genuinely mixed, but experimental data and biologic plausibility both support caution.^[6]
• Delaying surgical consultation or debridement to obtain imaging or await culture results when the clinical picture is strongly suggestive of necrotizing soft-tissue infection.^[8]
• Under-recognizing that streptococcal TSS carries a dramatically higher case-fatality rate than staphylococcal TSS, and under-triaging a patient with a compatible presentation and a possible streptococcal source as a result.^[3]
• Failing to arrange chemoprophylaxis for close contacts after a confirmed severe/invasive streptococcal case.^[3]
• Not offering explicit counseling on tampon/device avoidance after a menstrual TSS episode, given the real and meaningful recurrence risk with continued use.^[7]

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Empiric and Targeted Antibacterial Therapy — Staphylococcal TSS

Obtain blood and site cultures before the first dose whenever feasible. Always given in combination with clindamycin (see below), never as monotherapy.

Empiric and Targeted Antibacterial Therapy — Streptococcal TSS (STSS)

Always given in combination with clindamycin. Broaden empirically (e.g., vancomycin or piperacillin-tazobactam) if the source or organism is unclear, or a polymicrobial necrotizing infection is possible, pending cultures.

Toxin-Suppression Adjunct — Added to Every Regimen, Both Syndromes

Started from the first dose alongside the primary antibacterial agent — not reserved for treatment failure. See Choose Initial Treatment for the mechanistic rationale.

Antitoxin Adjunct — Severe or Refractory Disease

An adjunct to, never a substitute for, source control and antibiotics.

Hemodynamic Support

For shock refractory to adequate isotonic crystalloid resuscitation.

Analgesia and Antipyresis

Prefer acetaminophen over nonselective NSAIDs once significant soft-tissue infection or streptococcal disease is suspected (see Common Errors to Avoid).

Close-Contact Chemoprophylaxis — Confirmed Severe/Invasive Streptococcal Disease

Start as soon as possible, ideally within 24 hours of identifying a close contact; can still reasonably be offered up to about 7 days after the last contact with the index case.